Clene (CLNN) Stock
Small biotech company developing treatments for neurological disorders. Here's the price, business snapshot, and what's worth knowing about Clene in October 2026.
Clene Inc (CLNN) is a small‑cap, clinical‑stage biotechnology company (market cap roughly $86.8m) developing novel therapies aimed at neurological and related disorders. Investors should know Clene spends heavily on research and development and may not yet generate sustainable revenue; its value is driven largely by clinical trial progress, regulatory milestones and partner/licensing developments. That profile can produce meaningful upside if trials succeed, but also significant downside if programmes fail or funding becomes constrained. Liquidity can be limited in smaller stocks, amplifying price swings. Before considering an investment, review the company’s latest filings, cash runway and trial data, and compare its science and management team with peers. This summary is educational, not personalised advice — therapeutic development is inherently risky, and past performance does not predict future returns. Consider whether a speculative biotech aligns with your risk tolerance and investment horizon.
Clene (CLNN) Stock Forecast
Analyst price target, next 12 months
$65.50
+1588.1% vs today's $3.88
Price range over the last 12 months
Close to its 12-month low
Analysts covering Clene have a consensus 12-month target of $65.50, above the current price of $3.88.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Clene Inc.'s stock with a target price of $65.5, indicating strong potential growth.
Financial Health
Clene Inc is generating modest revenue and cash flow, with a decent profit margin on sales.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Ahead
Trial readouts and regulatory milestones can meaningfully affect value, though outcomes are uncertain and may increase volatility.
R&D-Driven Value
The company’s prospects hinge on science and trial results; strong data can create opportunities, but development is costly and risky.
Liquidity & Funding
As a small‑cap, cash runway and access to capital matter; funding news can shift the share price materially—consider suitability for your portfolio.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
